- Home
- BBDO vs ROIV Comparison
BBDO vs ROIV Comparison
Compare BBDO & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BBDO | ROIV |
|---|---|---|
| Founded | 1943 | 2014 |
| Country | Brazil | United Kingdom |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 33.6B | 28.7B |
| IPO Year | 2002 | 2021 |
Fundamental Metrics
Financial Performance| Metric | BBDO | ROIV |
|---|---|---|
| Price | $2.45 | $37.51 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 13 |
| Target Price | N/A | ★ $48.91 |
| AVG Volume (30 Days) | 146.7K | ★ 6.2M |
| Earning Date | 10-22-2026 | 11-09-2026 |
| Dividend Yield | ★ 7.15% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $8,260,000.00 |
| Revenue This Year | $10.16 | $530.75 |
| Revenue Next Year | $6.85 | $687.53 |
| P/E Ratio | $9.20 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.55 | $19.30 |
| 52 Week High | $4.16 | $42.50 |
Technical Indicators
Market Signals| Indicator | BBDO | ROIV |
|---|---|---|
| Relative Strength Index (RSI) | 27.19 | 58.00 |
| Support Level | N/A | $33.11 |
| Resistance Level | $3.23 | $37.89 |
| Average True Range (ATR) | 0.22 | 1.23 |
| MACD | -0.16 | 0.36 |
| Stochastic Oscillator | 1.16 | 82.15 |
Price Performance
Historical ComparisonAbout BBDO Banco Bradesco Sa
Banco Bradesco is Brazil's second-largest private bank, with about 10%-15% of deposits, and the largest insurance provider in Brazil, with roughly 20%-25% market share. The bank is majority controlled by the Bradesco foundation, a private nonprofit institution focused on education. The bank is also a major asset manager with high-single-digit market share. In 2016, Bradesco acquired the Brazilian operations of HSBC.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.